Protocol
Comprehensive geriatric assessment for older adults admitted to hospital
Across 29 trials with 13,766 older adults admitted to hospital, a comprehensive geriatric assessment (a team review of health, function, medicines and living situation) made it more likely they were alive and living at home 3 to 12 months later and less likely they moved to a nursing home.
At a glance
In hospital, a team can do a full review of an older person. They look at health, daily tasks, medicines, mood and home life, and they make a plan. In 29 trials, people who had this review were a bit more likely to be alive and back home months later. They were also less likely to move into a nursing home.
- What was measured
- Being alive and living at home 3 to 12 months after admission.
- How big
- People were 1.06 times as likely to be alive and living at home.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 28898390.
- Who it applies to
- Older adults admitted to hospital.
- Safety
- None identified.
- Compared with
- Usual hospital care.
- Certainty
- Grade B, resting on: Cochrane meta-analysis A study that pools the numbers from several trials into one combined estimate. of 29 randomized trials.
- What would change this grade
- Could rise to A with: Randomized trial of comprehensive geriatric assessment. Who: Older inpatients. Measured: Death and living at home. Length: At least 12 months.
- Cost
- No price recorded yet.
- Sources
- 1 study cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
Across 29 trials with 13,766 older adults admitted to hospital, a comprehensive geriatric assessment (a team review of health, function, medicines and living situation) made it more likely they were alive and living at home 3 to 12 months later and less likely they moved to a nursing home. Deaths did not change.
Why this letter
Why this gradeThe reasoning, and what the grade does not cover.
Grade B on being alive and living at home. A Cochrane review of 29 trials found, with high certainty, that comprehensive geriatric assessment raised the chance of being alive and at home by about 6% and cut nursing home admission by about 20% (Ellis et al., 2017; PMID 28898390).
WHY NOT Athe effect on living at home is small and deaths did not change.
WHAT THIS GRADE DOES NOT COVERfrail older people living in the community, where a separate Cochrane review is less clear, and any single test or medicine within the assessment.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: meta-analysis
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Alive and living at home (hard)
Last reviewed: November 2026
The trial that would change this grade.
Positive trials of this shape from independent research groups would move this entry to A.
Why the current trials fall short
A larger effect or a mortality benefit would be needed for A.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Geriatric Assessment among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Geriatric Assessment on ClinicalTrials.gov
Dose, form and timing
Not applicable; the outcome is living at home.
As studiedDose, form, population and duration for every use.
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
Safety
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 465 · November 2026 · First graded.
New record in the gap-report batch. Across 29 trials with 13,766 older adults admitted to hospital, a comprehensive geriatric assessment (a team review of health, function, medicines and living situation) made it more likely they were alive and living at home 3 to 12 months later and less likely they moved to a nursing home. Deaths did not change.PMID 28898390
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullOne paper, linked to its PubMed record.
Ellis et al. (Cochrane Database Syst Rev, 2017; PMID 28898390): 29 trials, 13,766 participants; alive and in own home at 3 to 12 months RR 1.06 (95% CI 1.01 to 1.10; high certainty); mortality RR 1.00; nursing home admission RR 0.80.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
"comprehensive geriatric assessment"[tiab] AND (randomized controlled trial[pt] OR meta-analysis[pt])PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →